GADD45B: A Potential Drug Target and Biomarker for Myeloid Differentiation Primary Response Protein MyD118

Target Name: GADD45B

NCBI ID: G4616

GADD45B

GADD45B: A Potential Drug Target and Biomarker for Myeloid Differentiation Primary Response Protein MyD118

Introduction

Myeloid differentiation primary response protein (MyD118) is a key regulator of myeloid cell proliferation and maturation. It plays a crucial role in the development and maintenance of the medulla microenvironment in the normal immune system. However, in some diseases, such as bone marrow failure, hematopoietic system tumors, etc., abnormal expression of MyD118 may lead to the progression and worsening of the disease. Therefore, it is of important clinical significance to study the biological functions of MyD118 and explore its possibility as a drug target or biomarker.

GADD45B: a gene related to MyD118

GADD45B is a protein belonging to the G-protein coupled receptor superfamily. It is widely expressed in multiple species and up-regulated in various human tumors. GADD45B is highly similar in structure and function to MyD118, so it is considered to be the interaction partner of MyD118.

Interaction of GADD45B and MyD118

GADD45B binds to MyD118 in cells and can affect the activity of MyD118. Activation of GADD45B can increase the phosphorylation level of MyD118, leading to hyperphosphorylation of MyD118, thereby inhibiting the activity of MyD118. In addition, GADD45B can also increase the binding of MyD118 to protein phosphatase, thereby inhibiting the phosphorylation of MyD118 and increasing the degradation of MyD118.

The role of GADD45B in tumors

Studies have shown that GADD45B is up-regulated in a variety of tumors, including leukemia, breast cancer, lung cancer, etc. The expression level of GADD45B is positively correlated with tumor progression and invasion ability. In addition, the expression level of GADD45B is negatively correlated with the survival rate of tumor patients. These results indicate that GADD45B may be a potential tumor target.

Possibility of GADD45B as a drug target or biomarker

Since GADD45B is up-regulated in a variety of tumors and is closely related to MyD118, GADD45B may be a potential drug target or biomarker. By inhibiting the activity of GADD45B, it is possible to slow down or prevent the progression and invasion of tumor cells. In addition, since the expression level of GADD45B is positively correlated with tumor progression and invasion ability, GADD45B may also serve as an important tumor biomarker.

in conclusion

GADD45B is a protein related to MyD118 and is up-regulated in a variety of tumors. The activity of GADD45B can affect the progression and invasion of tumor cells by inhibiting its activity. Therefore, GADD45B may be a potential drug target or biomarker that can be used to treat various tumors.

Protein Name: Growth Arrest And DNA Damage Inducible Beta

Functions: Involved in the regulation of growth and apoptosis. Mediates activation of stress-responsive MTK1/MEKK4 MAPKKK

The "GADD45B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GADD45B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets